Experimental drug targets harmful blood fats in early trial
NCT ID NCT06784349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called ALN-APOC3 in 32 adults with dyslipidemia (abnormal blood fat levels). The main goal was to check safety and how the drug affects fat levels in the blood. Participants were otherwise healthy and either not on statins or on a stable statin dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arensia Exploratory Medicine at the Republican Clinical Hospital
Chisinau, 2025, Moldova
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hormone therapy may shield menopausal hearts and brains — a trial puts it to the test
- Could vitamin d levels influence cholesterol in obese diabetes patients?
- Could a tropical oil and green exercise boost fat burning and calm your mind?
- Sugarcane supplement and exercise may team up to tame cholesterol
- Could a common cholesterol drug boost mood treatment?
- Could vinegar and fasting fix prediabetes cholesterol?